Corticosteroid treatment in 3 adult cases of EV-D68 and mycobacterial coinfection led to marked clinical improvement and near resolution of lung lesions over 6 to 9 months.
Case Report (n=3)
No
EV-D68 coinfection can exacerbate pulmonary inflammation in patients with mycobacterial disease, which may be improved by starting or intensifying corticosteroid therapy.
The threat of viral epidemics to long-standing diseases, such as mycobacterial infection, is constantly evolving. Enterovirus D68 (EV-D68) is an emerging cause of respiratory infection and has raised great interest since its first outbreak in 2014. Very few studies have been done to describe the clinical aspects of the coinfection of EV-D68 and mycobacteria, so this study was conducted to help round out the understanding of this coinfection pattern. We observed three adult cases of EV-D68 and mycobacteria, who were admitted to the first affiliated hospital of Zhejiang University in August/September 2024. Only one case had a definite past history of immunodeficient disease and received long-term corticosteroid treatment, and the other two were previously healthy. The diagnoses of EV-D68 and mycobacterial infection were all simultaneously confirmed through the metagenomic Next—Generation Sequencing in bronchoalveolar lavage fluid specimens. All three patients were presented with severe respiratory symptoms, such as fever, cough, dyspnea and tachypnea, without any manifestations of central nervous system involvement. The radiological findings in chest CT scans varied from patchy opacity to massive consolidation. The individualized anti-mycobacterium treatment showed little therapeutic effect, while the improvement of symptoms and pulmonary lesions in chest CT was observed after starting or intensifying the administration of corticosteroid. All patients had a marked clinical improvement when discharged from hospital, and it took about 6–9 months for the lung lesions of mycobacterial infections to nearly resolve. These cases illustrate the potential for EV-D68 coinfection to exacerbate pulmonary inflammation in patients with mycobacterial disease, highlighting the need for vigilance regarding possible viral coinfections in settings with a high tuberculosis burden, such as China.
Bao et al. (Wed,) conducted a case report in Enterovirus D68 and mycobacterial coinfection (n=3). Corticosteroid was evaluated on Clinical improvement and resolution of lung lesions. Corticosteroid treatment in 3 adult cases of EV-D68 and mycobacterial coinfection led to marked clinical improvement and near resolution of lung lesions over 6 to 9 months.